Most Recent Articles by Stan Grossman
A survey showed 67.3% of patient advocacy organizations received industry funding, while 11.9% received more than half of their funding from industry.
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
More Articles by Stan Grossman
Neurology Advisor Articles
- Coffee Consumption May Decrease Stroke Risk
- Prochlorperazine More Effective Than Ketamine for Headache Relief in the Emergency Department
- CTE Confirmed With Antemortem PET Imaging, Autopsy in Professional Football Player
- Intranasal Sumatriptan More Effectively Reduces Migraine-Associated Nausea
- Neuropsychiatric Conditions Common in Relatives of Patients With Amyotrophic Lateral Sclerosis
- Treating Cluster Headache: Weighing Current Therapies
- Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly
- NBT System Gets FDA Clearance for Depression Treatment
- Better Migraine Pain Relief With IV Non-Opioid Combination vs IV Hydromorphone
- FDA Approves Myasthenia Gravis Treatment
- Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug
- Nusinersen Improves Motor Function, Survival in Infants With Spinal Muscular Atrophy
- Noninvasive Brain Stimulation System Approved for Depression
- Hypertension Guidelines Updated by AHA/ACA
- Bone Mineral Density Associated With Intracranial Aneurysm Presence, Size